U.S. Markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
271.25-8.56 (-3.06%)
At close: 4:00PM EDT

271.23 -0.02 (-0.01%)
After hours: 7:42PM EDT

People also watch
Full screen
Previous Close279.81
Bid254.82 x 200
Ask271.43 x 100
Day's Range271.20 - 279.40
52 Week Range225.68 - 333.65
Avg. Volume1,610,146
Market Cap57.94B
PE Ratio (TTM)16.99
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 2 Pharma Buyout Targets That May Surprise You
    Motley Fool13 hours ago

    2 Pharma Buyout Targets That May Surprise You

    When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.

  • Benzinga4 days ago

    Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

    Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...

  • Capital Cube5 days ago

    Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : June 22, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 84. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more (Read more...)